10-Q: CytoDyn Reports Q1 Loss, Faces Going Concern Doubts

CytoDyn Inc. reported a net loss of $5.54 million for the quarter ended August 31, 2025, and disclosed substantial doubt about its ability to continue as a going concern.

Summary

• A net loss of $5.54 million was reported for the quarter ended August 31, 2025, a significant decline from a $19.23 million net income in the prior year, which was due to a one-time legal settlement.
• Cash and cash equivalents decreased by $2.57 million to $9.33 million as of August 31, 2025, from $11.90 million on May 31, 2025.
• Operating expenses increased to $4.95 million from a negative $22.44 million in the prior year, primarily due to the absence of the one-time clinical expense return.
• Research and development expenses increased to $3.23 million from a negative $24.05 million in the prior year, with clinical expenses rising due to the Phase II colorectal cancer trial.
• The company has an accumulated deficit of $893.3 million as of August 31, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern, dependent on securing additional capital and regulatory approvals.
• Stockholders will vote on November 21, 2025, to increase authorized common stock from 1.75 billion to 2.25 billion shares to facilitate future financing.
• SEC and DOJ investigations into the company were effectively closed in September 2025, with no further action required.

Sentiment

Score: 3

Explanation: The company reported a net loss and significant cash burn, leading to a 'going concern' warning. While SEC/DOJ investigations are closed, multiple other legal challenges persist, and future operations are heavily dependent on successful capital raises and regulatory approvals, which carry high uncertainty. The need for a shareholder vote to increase authorized shares highlights the immediate capital needs.

Positives

• SEC and DOJ investigations into the company were effectively closed in September 2025, with no further action required.
• Interest on convertible notes decreased by $489k (42%) to $676k for the quarter ended August 31, 2025, compared to the prior year.
• The company was not in default under its convertible notes as of the filing date, as noteholders waived certain default provisions.

Negatives

• Reported a net loss of $5.54 million for the quarter ended August 31, 2025, compared to a net income of $19.23 million in the same period last year (which included a one-time gain).
• Cash and cash equivalents decreased by $2.57 million to $9.33 million as of August 31, 2025.
• Net cash used in operating activities was $2.45 million, a decrease of $7.89 million compared to cash provided by operating activities in the prior year.
• Net cash provided by financing activities decreased by $9.79 million to a net use of $0.12 million, indicating no significant fundraising during the current period.
• Accumulated deficit increased to $893.3 million as of August 31, 2025.
• Stockholders' deficit increased to $(99,505)k from $(96,042)k.
• Outstanding convertible notes and accrued interest total $43.78 million as of August 31, 2025.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to recurring losses and an accumulated deficit of $893.3 million.
• Dependence on obtaining additional operating capital, completing leronlimab development, securing regulatory approval, and generating revenues.
• Inability to assure future funding will be available on acceptable terms or at all, potentially leading to discontinuation of operations or bankruptcy.
• Potential for significant dilution to stockholders from future sales of equity and debt securities.
• Restrictive provisions in existing convertible notes, including limitations on incurring additional indebtedness and future dilutive issuances, which could impair capital raising.
• Uncertainties and significant risks associated with future research and development activities, including pre-clinical and clinical studies.
• Regulatory determinations of leronlimab's safety and effectiveness by the FDA and other agencies.
• Risks related to the design, implementation, and conduct of clinical trials, including the possibility of unfavorable results.
• Market acceptance and marketability of any approved product, and competition from superior treatments.
• Ongoing legal proceedings, including securities class action lawsuits, shareholder derivative lawsuits, and an investor lawsuit seeking additional shares, with uncertain outcomes and potential material financial impact.
• Failure of stockholders to approve an increase in authorized common stock at the November 2025 annual meeting would limit the company's ability to engage in equity financing activities.

Future Outlook

The company plans to continue clinical development of leronlimab, including a Phase II trial for relapsed/refractory micro-satellite stable colorectal cancer and additional studies for other solid-tumor oncology indications like metastatic Triple-Negative Breast Cancer. It also intends to research and develop a new or modified long-acting version of leronlimab. Significant additional funding will be required, which the company aims to secure through equity and debt securities sales, as well as non-dilutive financing opportunities like license agreements and strategic partnerships.

Management Comments

• "Our forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements."
• "We intend that all forward-looking statements made in this quarterly report will be subject to the safe harbor protection of the federal securities laws."
• "We do not undertake any responsibility to update these forward-looking statements to address events or circumstances that occur after the date of this quarterly report."
• "We do not undertake any responsibility to update you on the occurrence of any unanticipated events that may cause actual results to differ from those expressed or implied by these forward-looking statements."

Industry Context

CytoDyn operates in the highly competitive and capital-intensive clinical-stage biotechnology sector, focusing on novel treatments like monoclonal antibodies. The company's reliance on leronlimab for multiple indications, particularly in oncology, places it in a challenging environment requiring substantial R&D investment and successful navigation of stringent regulatory pathways. The ongoing need for significant capital and the "going concern" warning are common challenges for clinical-stage biotechs without approved commercial products, highlighting the high-risk nature of drug development. The closure of SEC/DOJ investigations is a positive development, removing a significant overhang, but the company still faces multiple ongoing legal challenges, which can divert resources and attention from core R&D.

Corporate Governance

Legal Proceedings

• SEC and DOJ investigations were effectively closed in September 2025, with no further action required.
• Multiple ongoing securities class action lawsuits alleging false and misleading statements regarding leronlimab's efficacy for COVID-19, clinical trials (CD10, CD12), HIV BLA, and insider trading. The company denies allegations and cannot estimate potential loss.
• Multiple ongoing shareholder derivative lawsuits alleging breach of fiduciary duties, corporate waste, unjust enrichment, and insider trading. The company denies allegations and cannot estimate potential loss.
• An investor lawsuit filed in January 2025, claiming incorrect share issuance in 2022 and seeking additional shares. The company denies the claims and plans to vigorously defend itself.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing and future equity financing, potential negative impact from ongoing legal proceedings, and uncertainty regarding the company's ability to continue as a going concern. The vote to increase authorized shares is critical for future funding.
• Creditors (Convertible Noteholders) continue to convert debt into equity, indicating a preference for equity participation or a means of repayment, but also face risks associated with the company's going concern status.
• Employees: The company increased headcount, suggesting some stability, but the going concern warning implies potential future job insecurity if funding is not secured.
• Patients/Medical Community: Continued development of leronlimab offers potential future therapeutic options, but the success is contingent on clinical trial outcomes and regulatory approvals.

Next Steps

• Continue Phase II trial of leronlimab in patients with relapsed/refractory micro-satellite stable colorectal cancer.
• Conduct additional studies exploring leronlimab's therapeutic potential in other solid-tumor oncology indications, including metastatic Triple-Negative Breast Cancer.
• Continue research and development of a new or modified long-acting version of leronlimab.
• Seek additional operating capital through equity and debt securities sales, and non-dilutive financing.
• Stockholders to vote on an amendment to increase authorized common stock at the annual meeting on November 21, 2025.
• Continue to outsource manufacturing of leronlimab.
• Obtain approval to commercialize leronlimab from regulatory agencies.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a net loss, significant cash burn, and an explicit "going concern" warning. Its accumulated deficit is substantial, and it relies heavily on future capital raises, which will likely result in significant shareholder dilution. While the closure of SEC/DOJ investigations is a positive, multiple other complex and potentially costly legal proceedings remain. The company's core product, leronlimab, is still in clinical development, with no clear path to commercialization or profitability in the near term. The need for a shareholder vote to increase authorized shares underscores the immediate and critical funding challenges. Given the high financial risk, ongoing legal uncertainties, and lack of a revenue-generating product, the stock presents a high-risk investment profile.

Keywords

CytoDyn, leronlimab, biotechnology, clinical-stage, oncology, solid tumors, colorectal cancer, CCR5, SEC filing, 10-Q, financial results, going concern, clinical trials, drug development, equity financing, convertible notes, legal proceedings, FDA approval, shareholder vote